All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods. In addition, we provide a graphical depiction of the patient flow between or within different disease states for the countries considered in this report. These patient flow diagrams are provided at the regional level, but they may be requested for any specific country or forecast year.

DRG Epidemiology provides at least ten years of forecast data for the following ovarian cancer patient populations:

  • Diagnosed incident cases by stage distribution.
  • Diagnosed incident cases by BRCA distribution.
  • Diagnosed prevalent cases by drug-treatment potential.
  • Diagnosed early-stage DTP.
  • Diagnosed advanced-stage, first-line.

… and many more (details available on request).

Note: Coverage may vary by country and region.

Table of contents

  • Ovarian Cancer - Epidemiology - Emerging Markets Data
    • Introduction
      • Key Findings
        • Overview
          • Diagnosed Incidence of Ovarian Cancer per 100,000 People in 2017 and 2027
          • Depiction of the Patient Flow for Ovarian Cancer in 2017
          • Relative Sizes of the Contributing Factors to the Trend in Diagnosed Incident Cases of Ovarian Cancer Over the Next Ten Years
          • Analysis of Diagnosed Incident Cases of Ovarian Cancer Across the Countries Under Study by BRCA Mutation Status in 2017
          • Analysis of Diagnosed Incident Cases of Ovarian Cancer Across the Countries Under Study by Stage in 2017
      • Epidemiology Data
      • Methods
        • Newly Diagnosed Incidence
        • Stage Distribution
        • BRCA Status
        • Diagnosed Prevalence
        • Recurrent Incidence
        • Drug-Treatable Populations
        • Lifetime DALYs Gained
      • Reference Materials
        • Literature Review
          • Studies Included in the Analysis of Ovarian Cancer
          • Studies Excluded from the Analysis of Ovarian Cancer
        • Risk/Protective Factors
          • Risk/Protective Factors for Ovarian Cancer
        • Bibliography

    Author(s): Alison Isherwood, MSc, MRes, PhD

    Alison Isherwood, B.Sc., M.Res., M.Sc., Ph.D. joined Decision Resources Group in 2008, as an Epidemiologist. Alison holds a B.Sc. in Medical Microbiology, Masters by Research in the Life Sciences and a M.Sc. in Epidemiology all from the University of Edinburgh. Prior to joining Decision Resources Inc., she was working on her Ph.D. in Molecular Virology, specializing on the severe acute respiratory syndrome (SARS) coronavirus, at the University of Reading. In her role at Decision Resources Group, Alison is currently an Epidemiology team lead as well as project managing custom epidemiology work in multiple therapy areas. Alison’s area of specialization at DRG is cancer, particularly breast cancer.


    Related Reports

    Ovarian Cancer - Landscape & Forecast - Disease Landscape & Forecast

    The ovarian cancer treatment algorithm is rapidly evolving. For decades, chemotherapy was the standard of care, but now, with the introduction of Roche/Genentech/Chugai’s Avastin and three PA...

    View Details

    Ovarian Cancer | Disease Landscape and Forecast | G7 | 2020

    The ovarian cancer treatment algorithm is rapidly evolving. For decades, chemotherapy was the standard of care, but now, with the introduction of Roche/Genentech/Chugai’s Avastin and three PARP inh...

    View Details

    Ovarian Cancer - Unmet Need - Detailed, Expanded Analysis (US/EU)

    The poly ADP ribose polymerase (PARP) inhibitors, such as AstraZeneca’s Lynparza, GSK’s Zejula, and Clovis Oncolo...

    View Details

    Ovarian Cancer - Epidemiology - Mature Markets

    DRG Epidemiology's coverage of ovarian cancer comprises epidemiological estimates of key patient populations across 45 countries worldwide. We...

    View Details